Published in Cancer Weekly, March 6th, 2007
"Several approaches have been employed to target uPAR with the aim of disrupting its ligand-independent action or interaction with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.